214 related articles for article (PubMed ID: 16139439)
1. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
Gunawardena K; Campbell LD; Meikle AW
Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with vitamins C plus E inhibits survivin and human prostate cancer cell growth.
Gunawardena K; Campbell LD; Meikle AW
Prostate; 2004 May; 59(3):319-27. PubMed ID: 15042608
[TBL] [Abstract][Full Text] [Related]
3. Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells.
Gunawardena K; Murray DK; Meikle AW
Cancer Detect Prev; 2002; 26(2):105-13. PubMed ID: 12102144
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
5. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
6. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
7. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
[TBL] [Abstract][Full Text] [Related]
8. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
[TBL] [Abstract][Full Text] [Related]
9. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells.
Gupta S; Afaq F; Mukhtar H
Oncogene; 2002 May; 21(23):3727-38. PubMed ID: 12032841
[TBL] [Abstract][Full Text] [Related]
10. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
11. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
12. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J
Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261
[TBL] [Abstract][Full Text] [Related]
13. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells.
Mori A; Lehmann S; O'Kelly J; Kumagai T; Desmond JC; Pervan M; McBride WH; Kizaki M; Koeffler HP
Cancer Res; 2006 Mar; 66(6):3222-9. PubMed ID: 16540674
[TBL] [Abstract][Full Text] [Related]
14. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
[TBL] [Abstract][Full Text] [Related]
15. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
16. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
17. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
18. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
19. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
